Download PDF
CC BY-NC-ND 4.0 · Avicenna J Med 2018; 8(01): 34-36
DOI: 10.4103/ajm.AJM_127_17
CASE REPORT

Nivolumab-induced new-onset seronegative rheumatoid arthritis in a patient with advanced metastatic melanoma: A case report and literature review

Ammar Haikal
Department of Internal Medicine, University of Kansas Medical Center, Kansas, USA
,
E Borba
Department of Orthopedic Surgery, Cajuru Hospital, Curitiba, Brazil
,
Taqui Khaja
Department of Internal Medicine, University of Kansas Medical Center, Kansas, USA
,
Gary Doolittle
Department of Oncology, University of Kansas Medical Center, Kansas, USA
,
Paul Schmidt
Department of Rheumatology, University of Kansas Medical Center, Kansas, USA
› Author Affiliations Financial support and sponsorship Nil.
› Further Information
   Permissions and Reprints

Abstract

Immune-related adverse events have been reported in patients treated with anti-programmed death-1 receptor drugs such as nivolumab. We present a case of a new-onset seronegative rheumatoid arthritis in a patient with metastatic melanoma treated with nivolumab.

Keywords

Immune-related adverse event - immunotherapy - inflammatory arthropathy - nivolumab - rheumatoid arthritis


Publication History

Article published online:
12 August 2021

© 2018. Syrian American Medical Society. This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial-License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. (https://creativecommons.org/licenses/by-nc-nd/4.0/).

Thieme Medical and Scientific Publishers Private Ltd.
A-12, Second Floor, Sector -2, NOIDA -201301, India

 

  • References

  • 1 Hamanishi J, Mandai M, Matsumura N, Abiko K, Baba T, Konishi I. et al. PD-1/PD-L1 blockade in cancer treatment: Perspectives and issues. Int J Clin Oncol 2016; 21: 462-73
    CrossrefPubMedGoogle Scholar
  • 2 Medina PJ, Adams VR. PD-1 pathway inhibitors: Immuno-oncology agents for restoring antitumor immune responses. Pharmacotherapy 2016; 36: 317-34
    CrossrefPubMedGoogle Scholar
  • 3 Guibert N, Mazières J. Nivolumab for treating non-small cell lung cancer. Expert Opin Biol Ther 2015; 15: 1789-97
    CrossrefPubMedGoogle Scholar
  • 4 Sunshine J, Taube JM. PD-1/PD-L1 inhibitors. Curr Opin Pharmacol 2015; 23: 32-8
    CrossrefPubMedGoogle Scholar
  • 5 Alexander W. The checkpoint immunotherapy revolution: What started as a trickle has become a flood, despite some daunting adverse effects; new drugs, indications, and combinations continue to emerge. P T 2016;41:185-91.
  • 6 Francisco LM, Sage PT, Sharpe AH. The PD-1 pathway in tolerance and autoimmunity. Immunol Rev 2010; 236: 219-42
    CrossrefPubMedGoogle Scholar
  • 7 Buqué A, Bloy N, Aranda F, Castoldi F, Eggermont A, Cremer I. et al. Trial watch: Immunomodulatory monoclonal antibodies for oncological indications. Oncoimmunology 2015; 4: e1008814
    CrossrefPubMedGoogle Scholar
  • 8 Eigentler TK, Hassel JC, Berking C, Aberle J, Bachmann O, Grünwald V. et al. Diagnosis, monitoring and management of immune-related adverse drug reactions of anti-PD-1 antibody therapy. Cancer Treat Rev 2016; 45: 7-18
    CrossrefPubMedGoogle Scholar
  • 9 Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 2016; 26: 202-4
    CrossrefPubMedGoogle Scholar
  • 10 Syrigos K, Tsagouli S, Grapsa D. Nivolumab-induced recurrence of rheumatoid arthritis in a patient with advanced non-small cell lung cancer: A Case report. Ann Intern Med 2016; 165: 894-5
    CrossrefPubMedGoogle Scholar
  • 11 Raptopoulou AP, Bertsias G, Makrygiannakis D, Verginis P, Kritikos I, Tzardi M. et al. The programmed death 1/programmed death ligand 1 inhibitory pathway is up-regulated in rheumatoid synovium and regulates peripheral T cell responses in human and murine arthritis. Arthritis Rheum 2010; 62: 1870-80
    PubMedGoogle Scholar
  • 12 Johnson DB, Balko JM, Compton ML, Chalkias S, Gorham J, Xu Y. et al. Fulminant myocarditis with combination immune checkpoint blockade. N Engl J Med 2016; 375: 1749-55
    CrossrefPubMedGoogle Scholar
  • 13 Singh JA, Saag KG, Bridges SL Jr, Akl EA, Bannuru RR, Sullivan MC. et al. 2015 American college of rheumatology guideline for the treatment of rheumatoid arthritis. Arthritis Care Res (Hoboken) 2016; 68: 1-25
    CrossrefPubMedGoogle Scholar